Mangoceuticals enters marketing agreement with Marius to market, sell KYZATREX

Mangoceuticals announces that it has entered into a Marketing Agreement with Marius Pharmaceuticals to market and sell KYZATREX, an FDA-approved oral Testosterone Replacement Therapy product, under the program, ‘PRIME’ by MangoRx. PRIME will be available on MangoRx’s telemedicine platform with an anticipated launch date of January 31, 2024. Shalin Shah, CEO of Marius, shared, “This expansion into telehealth marks an important step in the care of Testosterone Deficient patients. Testosterone Deficiency is a serious chronic disease and has been inadequately addressed by previous generations of products. KYZATREX marks a shift in the treatment paradigm and a meaningful opportunity for patients seeking to restore optimal testosterone levels. Marius is excited to partner with MangoRx as an innovative partner in the DTC marketplace. We look forward to the Mango team bringing more awareness around the significance of Testosterone as a metabolic hormone and its role in optimal health for men with Low T.”